NCT03430856: A trial that was reported late by Biocon Limited
This trial has reported, although it was 63 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03430856 |
|---|---|
| Title | An Open Label, Multi-center, Randomized, Parallel Group Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Insulin Tregopil (IN-105) Compared With Insulin Aspart in the Treatment of Patients With Type 2 Diabetes Mellitus on Stable Dose of Metformin and Insulin Glargine |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 26, 2017 |
| Completion date | Feb. 6, 2019 |
| Required reporting date | Feb. 6, 2020, midnight |
| Actual reporting date | April 9, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 63 |